Literature DB >> 8069540

Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats.

G Borchard1, J Kreuter.   

Abstract

Radiolabelled poly(methylmethacrylate) (PMMA) nanoparticles were coated with rat serum albumin (RSA), serum and inactivated serum, to examine the influence of these blood components on the body distribution of a model colloidal drug carrier. The particles were incubated overnight at 37 degrees C either in a 1% solution of RSA in phosphate buffered saline (PBS) or in serum obtained from the rats. A suspension of nanoparticles in PBS was used as a control. Serum complement inactivation was achieved by storage at 56 degrees C for 30 min. The suspensions were then injected intravenously via the tail vein of Wistar rats. The animals were sacrificed at five different time points (30 min, 2 h, 6 h, 24 h, and 7 d after injection) and two samples of each organ and two blood samples were weighed into scintillation vials. The radioactivity of each sample was then measured in a Beckman scintillation counter. Coating with RSA led to no significant change in the body distribution of the particles, whereas incubation in serum, especially with complement inactivation prior to injection, very significantly reduced the uptake of particles into the organs of the reticuloendothelial system (RES), e.g., liver, spleen, and bone marrow. At the same time, much higher concentrations of nanoparticles were observed in the serum and in non-RES organs and peripheral tissues (kidneys, muscles, and intestine). This effect was most pronounced after 30 min, but was still observable after 7 d.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8069540     DOI: 10.3109/10611869308998760

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs.

Authors:  E Merisko-Liversidge; P Sarpotdar; J Bruno; S Hajj; L Wei; N Peltier; J Rake; J M Shaw; S Pugh; L Polin; J Jones; T Corbett; E Cooper; G G Liversidge
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 2.  Drug targeting with nanoparticles.

Authors:  J Kreuter
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

3.  Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Authors:  Rebecca Voltan; Arianna Castaldello; Egidio Brocca-Cofano; Giuseppe Altavilla; Antonella Caputo; Michele Laus; Katia Sparnacci; Barbara Ensoli; Silvia Spaccasassi; Marco Ballestri; Luisa Tondelli
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

4.  The role of serum complement on the organ distribution of intravenously administered poly (methyl methacrylate) nanoparticles: effects of pre-coating with plasma and with serum complement.

Authors:  G Borchard; J Kreuter
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 5.  Albumin Nanovectors in Cancer Therapy and Imaging.

Authors:  Alessandro Parodi; Jiaxing Miao; Surinder M Soond; Magdalena Rudzińska; Andrey A Zamyatnin
Journal:  Biomolecules       Date:  2019-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.